Does β-blocker prophylaxis improve survival after major noncardiac surgery?

Terblanche, Marius; Adhikari, Neill K. J.; Scales, Damon C.
October 2005
CMAJ: Canadian Medical Association Journal;10/11/2005, Vol. 173 Issue 8, p874
Academic Journal
Presents a study on the relation of β-blockade therapy and the risk of death after major noncardiac surgery. Number of study participants; Limitations of the study; Implications of the study.


Related Articles

  • Antiarrhythmic Action of β-Blockers: Potential Mechanisms. Dorian, Paul // Journal of Cardiovascular Pharmacology & Therapeutics;Jun2005 Supplement, Vol. 10 Issue 2S, pS15 

    The article reports that multiple direct and indirect mechanisms of adrenergic action on the heart may benefit from the known antiarrhythmic actions of β-blocker therapy and other interventions that decrease sympathetic tone. The blockers in the heart are responsible for the primary direct...

  • Beta-blockers and adverse effects: Dispelling the myths. Deedwania, Prakash C. // Patient Care;Jul2002, Vol. 36 Issue 9, p28 

    Focuses on the use of beta-blockers for the treatment of cardiovascular disease (CVD). Rationale for beta-blocker use in CVD; Underutilization of beta-blockers in treating CVD; Guidelines for beta-blocker use. INSET: This article at a glance.

  • Teoptic.  // Royal Society of Medicine: Medicines;2002, p527 

    The article presents information on Teoptic, a proprietary, prescription-only preparation of the beta-blocker carteolol hydrochloride. It can be used for glaucoma treatment, and is available as eye-drops.

  • What doesn't kill you. Martindale, Diane // New Scientist;10/25/2003, Vol. 180 Issue 2418, p38 

    Dishing out drugs that make your symptoms worse seems like a rash, even dangerous way to treat patients. Miracle workers rarely come back for an encore, but in the world of heart medicine one little miracle is bucking the trend. Beta blockers were invented in 1964 and quickly became the most...

  • Effects of Dantrolene Treatment on Ventricular Electrophysiology and Arrhythmogenesis in Rats With Chronic β-Adrenergic Receptor Activation. Liu, Tao; Shi, Shao-bo; Qin, Mu; Huang, Cong-xin // Journal of Cardiovascular Pharmacology & Therapeutics;Jul2015, Vol. 20 Issue 4, p414 

    Dantrolene, which is primarily used to treat malignant hyperthermia, has recently been suggested for the prevention of arrhythmogenesis in various animal models. In this study, the effects of dantrolene treatment on electrophysiological properties and ventricular arrhythmias (VAs) in rats with...

  • About beta blockers.  // Mayo Clinic Health Letter;Jul2012, Vol. 30 Issue 7, p7 

    The article offers information on beta blockers, drugs that are used in managing heart health.

  • Expanding Indications for Beta-Blockers in Heart Failure. Braunwald, Eugene // New England Journal of Medicine;05/31/2001, Vol. 344 Issue 22, p1711 

    Editorial. Discusses the use of beta-blockers to treat heart failure. Two studies in this issue which report on the effects of beta-blockade and which appear to have come to opposite conclusions; Prudence of remaining alert to racial differences in the response to beta-blockers in future...

  • NEUROPROTECTION. Serle, Jenet B. // Ophthalmology Times;1/1/2005, Vol. 30 Issue 1, special section p5 

    This article reports that neuroprotection attempts to block the final common pathway of a variety of insults that lead to ganglion cell death. Numerous potential treatment modalities for neural protection have been under investigation. Some research has focused on stabilizing calcium homeostasis...

  • Glau-opt.  // Royal Society of Medicine: Medicines;2002, p268 

    The article provides information on the drug Glau-opt. It is a proprietary, prescription-only preparation of the beta-blocker timolol maleate. It can be used for glaucoma treatment, and is available as eye-drops.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics